Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
Georgina Gener‐Ricos, Fadi Haddad, Koji Sasaki, Ghayas C. Issa, Jeffrey Skinner, Lucia Masárová, Gautam Borthakur, Yesid Alvarado, Guillermo Garcia‐Manero, Elias Jabbour, Hagop M. Kantarjian
Topics & Concepts
DasatinibMedicineCumulative incidenceInternal medicineMyeloid leukemiaCohortTyrosine-kinase inhibitorIncidence (geometry)ImatinibGastroenterologyOncologyCancerPhysicsOpticsChronic Myeloid Leukemia TreatmentsEosinophilic Disorders and SyndromesAcute Myeloid Leukemia Research